Engineering Conferences International

ECI Digital Archives
Vaccine Technology VIII

Proceedings

6-12-2022

Production and purification of an immunogenic G protein of
rabies virus from S2 insect cells
Renato Mancini Astray
Livia Pillati
Mayra Pereira Rocca
Flavia Ferreira Barbosa
Helio Langoni

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Authors
Renato Mancini Astray, Livia Pillati, Mayra Pereira Rocca, Flavia Ferreira Barbosa, Helio Langoni, Benedito
Menozzi, Soraia Attie Calil Jorge, and Elisabeth Augusto

PRODUCTION AND PURIFICATION OF AN IMMUNOGENIC RECOMBINANT G PROTEIN OF RABIES
VIRUS FROM S2 INSECT CELLS
Renato Mancini Astray, Instituto Butantan
renato.astray@butantan.gov.br
Livia Pillati, Instituto Butantan
Mayra Pereira Rocca, Instituto Butantan
Flavia Ferreira Barbosa, Instituto Butantan
Helio Langoni, Unesp
Benedito Menozzi, Unesp
Soraia Attie Calil Jorge, Instituto Butantan
Elisabeth Augusto, Unifesp
Key Words:

Rabies glycoprotein; S2 insect cells

Rabies virus is still a major public health concern in under developed countries of Africa, Asia and Latin
America. WHO estimates that almost 55.000 people die from rabies annually. Although Rabies virus strains
from dogs still are the main responsible of causing human disease, the increasing case numbers of bat virus
strains being transmitted to humans in America raises concerns. The called secondary transmission cycle of
rabies involves cats or dogs which are exposed to contaminated bats and then transmit it to humans. Combating
this type of transmission requires new strategies for disease control, including new vaccines. Particularly for
cats, the current rabies vaccines have demonstrated to cause vaccine-associated sarcoma as a serious side
effect. New rabies vaccines using recombinant technology have been proposed using the Rabies Glycoprotein
(G) as antigen. The expression of this molecule in S2 insect cells has already proved the ability of this cell line to
produce an immunogenic protein. Although this antigen is recognized as the main protein necessary for
protection upon immunization, its utilization as a recombinant vaccine has been impaired by difficulties in its
production and mainly purification steps. The G protein was expressed as a membrane bound protein
in Drosophila melanogaster S2 cells. This membrane G protein was further solubilized using a standardized
solution containing detergent and purified in a novel methodology using affinity chromatography resulting in
protein recoveries up to 96 %. The membrane protein and the purified G were used for mice immunization,
using or not ISCOM adjuvant resulting in good levels of specific antibodies and neutralizing antibodies. When
immunized mice were submitted to lethal rabies virus challenge, the preparations showed to confer protection
levels similar to that of commercially available veterinary rabies vaccine. A flow path from the production,
purification, formulation and immunization against Rabies using a recombinant G protein is presented as a
promisor veterinary vaccine candidate.
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